Celularity Inc. to Host Investor and Analyst Research & Development Day

FLORHAM PARK, N.J., April 22, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative and cellular medicine company developing placental-derived allogeneic cell therapies and advanced

GlobeNewswireApr 22 08:00 ET

Express News | Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing

Moomoo 24/7Apr 19 17:30 ET

Celularity Abstract "Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials" Accepted at ORS Tendon Conference 2024

Celularity Inc. (Nasdaq: CELU) today announced that its abstract entitled "Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials" was accepted by the Orthopedic Research Society (ORS) Tendon Conference, which will be held from May 30 - June 1, 2024 at the Mayo Clinic in Rochester, MN.

GlobeNewswireApr 18 16:30 ET

Express News | Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024; Implements Planned 2024 SG&a Reductions and Manufacturing Ramp for Advanced Biomaterial Products

Moomoo 24/7Apr 15 08:00 ET

Celularity To Present Data Showing Senescent Cell Elimination By Off-The-Shelf Natural Killer Cells Derived From Human Placental Cells

Celularity Inc. (NASDAQ:CELU) ("Celularity"), a biotechnology company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today that it will present in

BenzingaApr 8 09:03 ET

Celularity Receives Healthcare Common Procedure Coding System Q Code Approval From The U.S. Centers For Medicare & Medicaid Services For Biovance 3L

Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, today announced that the U.S. Ce

BenzingaMar 26 09:02 ET